Currently there are no approved drug delivery method for gene therapy
R&D Focus
AI-based drug delivery platform
Innovative Solution
Mana.bio uses technology powered by the integration of machine learning and nanotechnology in order to identify formulations of lipid nanoparticle systems and focus on gene therapy including DNA and RNA-based therapeutics, and vaccines
Solution Effectiveness
Mana.bio LNPs can deliver RNA payloads to specific tissues more safely and effectively
Investment Funding
Last Funding Stage
Seed
Total Funding Amount
$24.5M
Last Funding Amount
$19.5M
Last Funding Date
12-Oct-23
Startup Stage
Early-Stage
Lead Investors
Andreessen Horowitz, Base4 Capital, Technion Israel Institute of Technology, LionBird, NFX
People
Founders
Yogev Debbi
Roy Nevo
Avi Schroeder
Kira Radinsky
CEO
Yogev Debbi
Products
Demo Product or Complete Product?
Development
Awards and Recognitions
Media Apperance
Techcrunch, Ai tech park
M&A and Collabs
Collab
Mana.bio partners with Ginkgo Bioworks to add delivery capabilities as part of its Technology Network Platform launch
